Home › Breast Cancer › Missouri
Breast Cancer clinical trials in Missouri
73 studies for Breast Cancer are looking for participants at sites in Missouri.
Cities in Missouri
- St. Louis63 studies
- Kansas City34 studies
- Springfield11 studies
- O'Fallon7 studies
- Saint Joseph7 studies
- Columbia7 studies
- Lee's Summit7 studies
- Cape Girardeau4 studies
- Joplin4 studies
- Rolla3 studies
WashU DIEP Flap Video and Patient Understanding Improvement
- Washington University School of Medicine, St Louis
Recruiting
Ages 18 and older · Women · Updated Nov 13, 2026 · NCT06864754Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Saint Luke's Cancer Institute, Kansas City
- Washington University School of Medicine, St Louis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT05696626An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
- Washington University in St Louis, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07222267S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Saint Louis Cancer and Breast Institute-Ballwin, Ballwin
- Saint Francis Medical Center, Cape Girardeau
- Capital Region Southwest Campus, Jefferson City
- and 10 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03418961Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
- Research Facility, St Louis
RecruitingPhase 1/2
All ages · All sexes · Updated Nov 12, 2026 · NCT06590857A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Saint Luke's Hospital of Kansas City, Kansas City
- Washington University School of Medicine, St Louis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06827236A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Saint Luke's Cancer Institute ( Site 0059), Kansas City
- Washington University Siteman Cancer Center ( Site 0031), St Louis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06966700ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Washington University School of Medicine- Siteman Cancer Center, St Louis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07007559The Vanguard Study: Testing a New Way to Screen for Cancer
- Saint Luke's Hospital of Kansas City, Kansas City
- CoxHealth South Hospital, Springfield
- Washington University School of Medicine, St Louis
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Nov 6, 2026 · NCT06995898A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Washington University, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07029399Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Mercy Health - Sindelar Cancer Center, St Louis
- Mercy Health - Pratt Cancer Center, St Louis
Recruiting
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07214532Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Washington University School of Medicine- Siteman Cancer Center, St Louis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06982521A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Saint Luke's Cancer Institute, Kansas City
- Oncology Hematology Associates, Springfield
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07174336A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- HCA Midwest Health, Kansas City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06790693E-Mindfulness Approaches for Living After Breast Cancer
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Lake Regional Hospital, Osage Beach
- Heartland Regional Medical Center, Saint Joseph
- and 4 more
RecruitingPhase 3
Ages 18 to 50 · All sexes · Updated Nov 4, 2026 · NCT06748222A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Washington University School of Medicine, St Louis
RecruitingPhase 2
Ages 18 and older · Women · Updated Nov 4, 2026 · NCT07287098Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- and 21 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Saint Louis Cancer and Breast Institute-Ballwin, Ballwin
- Parkland Health Center - Farmington, Farmington
- and 16 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06418204A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Washington University School of Medicine in St. Louis, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07213791A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Washington University, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07114601Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- and 29 more
RecruitingPhase 3
Ages 18 to 60 · Women · Updated Nov 4, 2026 · NCT05879926ChatGPT & Surgeon Synergy: Redefining Breast Reconstruction Consultations for Enhanced Patient Engagement and Satisfaction
- Washington University School of Medicine, St Louis
Recruiting
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06981208To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
- HCA Midwest Division, Kansas City
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07368998Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- Washington University School of Medicine, St Louis
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT00353483ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Saint Luke's Hospital of Kansas City, Kansas City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07173751A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Washington University, Siteman Cancer Center, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06774963A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Washington Univ. School of Medicine, St Louis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT07109726EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
- Saint Luke's Hospital of Kansas City, Kansas City
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06401421A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Washington University, School of Medicine, St Louis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06172478A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Washington University Siteman Cancer Center, St Louis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT07100106A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- Washington University School of Medicine - Siteman Cancer Center, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07383506Navigation Interventions for Patients With Breast Cancer and High-risk Social Determinants of Health
- Washington University School of Medicine, St Louis
Recruiting
Ages 18 and older · Women · Updated Oct 21, 2026 · NCT07781800A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Siteman Cancer Center - St Peters, City of Saint Peters
- Missouri Cancer Associates, Columbia
- Siteman Cancer Center - West County, Creve Coeur
- and 8 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT07062965Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
- Washington University School of Medicine, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 16, 2026 · NCT07137416Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
- Washington University School of Medicine, St Louis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06374459A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Saint Luke's Cancer Institute ( Site 0027), Kansas City
- Washington University School of Medicine ( Site 0076), St Louis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06312176A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, St Louis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT05123482Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Saint Luke's Cancer Institute, Kansas City
- Washington University School of Medicine in Saint Louis, St Louis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT06757634BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
- Washington University School of Medicine, St Louis
Recruiting
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT05977036Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- St. Lukes Hospital of Kansas City, Kansas City
- Washington University School of Medicine, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06625775From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.